临床前CDMO研发筛选相关化合物

CDMO是Contract Development and Manufacturing Organization的缩写，即合同定制研发生产组织。它是一种为制药企业及生物技术公司提供医药（特别是创新药）工艺研发及制备、工艺优化、放大生产、注册和验证批生产以及商业化生产等定制服务的机构. 在传统代工基础上增加了研发和工艺优化能力，是高技术壁垒的工艺研发能力与规模生产能力的深度结合. 1, 工艺开发与优化：创新性合成路线设计、工艺参数优化. 2, 中试放大：实验室工艺向规模化生产的转化 3, 注册批生产：支持客户新药申报的验证批生产. 4, 商业化生产：药品上市后的大规模生产供应. 全球医药CDMO行业保持较高景气度。根据弗若斯特沙利文预测：2026年全球CDMO市场规模：预计达1,189亿美元 2033年全球CDMO市场规模：预计达3,385亿美元. CDMO作为医药产业链专业化分工的产物，已经从单纯的CMO代工模式升级为"研发+生产"一体化的高附加值服务。当前，在多肽、ADC、CGT等新型药物赛道的驱动下，全球及中国CDMO市场保持高速增长。中国CDMO企业凭借完整的供应链体系、工程师红利和一体化服务能力，全球市占率有望持续提升，行业正从"成本优势"竞争迈向"体系优势"竞争的新阶段。
如有产品调研服务, 请致函联系我们

客户展示

临床前CDMO研发化合物筛选

CAS: 24280-93-1

Mycophenolic acid

中文名称:霉酚酸
CAS号:24280-93-1
分子式: C17H20O6 分子量: 320.34
产品形式: free base
研发状态: Not yet recruiting
研发用途: Hyperglycemia; Renal Transplant Complication Primary Non-Function; Diabetes
研究机构: Rigshospitalet Denmark; Aarhus University Hospital; Odense University Hospital
研发日期: April 1 2024
研发阶段: Phase 4
Mycophenolic acid (Mycophenolate, RS-61443) is a potent IMPDH inhibitor and the active metabolite of an immunosuppressive drug, used to prevent rejection in organ transplantation.

CAS: 242478-38-2

Solifenacin succinate

中文名称:琥珀酸索利那新
CAS号:242478-38-2
分子式: C23H26N2O.C4H6O4 分子量: 480.55
产品形式: Succinate
研发状态: Recruiting
研发用途: Urge Incontinence; Urgency-frequency Syndrome
研究机构: Istanbul University; Arnavutkoy State Hospital
研发日期: June 3 2021
研发阶段: --
Solifenacin succinate (YM905) is a urinary antispasmodic of the antimuscarinic class.

CAS: 24169-02-6

Econazole nitrate

中文名称:硝酸益康唑
CAS号:24169-02-6
分子式: C18H15Cl3N2O.HNO3 分子量: 444.70
产品形式: Nitrate
研发状态: Completed
研发用途: Interdigital Tinea Pedis
研究机构: AmDerma; AmDerma Pharmaceuticals LLC
研发日期: Sep-11
研发阶段: Phase 2
Econazole Nitrate (NSC 243115,Spectazole) is a Ca2+ channel blocker, used as an antifungal medicine that fights infections caused by fungus.

CAS: 2416874-75-2

KB-0742 Dihydrochloride

CAS号:2416874-75-2
分子式: C16H25N5.2ClH 分子量: 360.33
产品形式: Dihydrochloride
研发状态: Recruiting
研发用途: Relapsed Solid Tumors; Refractory Solid Tumors; Non-Hodgkin Lymphoma
研究机构: Kronos Bio
研发日期: February 8 2021
研发阶段: Phase 1 : Phase 2
KB-0742 Dihydrochloride is a potent, selective, and orally bioavailable small molecule inhibitor of the transcription elongation cofactor CDK9 with IC50 of 6 nM for CDK9/cyclin T1 inhibition at 10 μM ATP.

CAS: 2416131-46-7

NX-2127

CAS号:2416131-46-7
分子式: C39H45N9O5 分子量: 719.83
产品形式: free base
研发状态: Active not recruiting
研发用途: Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL); Waldenstrom Macroglobulinemia (WM); Mantle Cell Lymphoma (MCL); Marginal Zone Lymphoma (MZL); Follicular Lymphoma (FL); Diffuse Large B-cell Lymphoma (DLBCL); Primary Central Nervous System Lymphoma (PCNSL)
研究机构: Nurix Therapeutics Inc.
研发日期: May 5 2021
研发阶段: Phase 1
NX-2127 is a unique, potent inhibitor of BTK that prevents its functions by catalyzing the ubiquitylation and proteasomal degradation of BTK rather than via direct binding. NX-2127 stimulates T cell activation and increases IL-2 production in primary human T Cells.

CAS: 241479-67-4

Isavuconazole

中文名称:艾沙康唑
CAS号:241479-67-4
分子式: C22H17F2N5OS 分子量: 437.47
产品形式: free base
研发状态: Recruiting
研发用途: Invasive Fungal Disease
研究机构: Pfizer
研发日期: February 7 2023
研发阶段: Phase 4
Isavuconazole (BAL-4815, RO-0094815) is a new extended-spectrum triazole with activity against yeasts, molds, and dimorphic fungi that inhibits cytochrome P450 (CYP)-dependent 14α-lanosterol demethylation, which is essential for fungal cell membrane ergosterol synthesis.